首页 > 最新文献

Acta pharmaceutica Sinica最新文献

英文 中文
Medicinal chemistry strategies in seeking coronavirus inhibitors 寻找冠状病毒抑制剂的药物化学策略
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-04-01 DOI: 10.16438/J.0513-4870.2020-0131
Jing Li, Xiangyi Jiang, Shujing Xu, Q. Cui, Ruikun Du, Dongwei Kang, P. Zhan, L. Rong, Xin Liu
The epidemic caused by coronavirus poses a serious threat to human health, but there is no specific drug or vaccine for the treatment of this kind of virus infection Herein, this article selects typical case studies in recent years and reviews the medicinal chemistry strategies of anti-SARS-CoV, MERS-CoV and other coronavirus drugs from the perspective of medicinal chemistry, and tries to provide some clues to current drug research against-SARS-CoV-2
冠状病毒引起的疫情对人类健康构成严重威胁,但目前尚无治疗此类病毒感染的特异性药物或疫苗。本文选取近年来的典型病例研究,从药物化学的角度综述了抗sars - cov、MERS-CoV等冠状病毒药物的药物化学策略,试图为当前抗sars - cov -2药物研究提供一些线索
{"title":"Medicinal chemistry strategies in seeking coronavirus inhibitors","authors":"Jing Li, Xiangyi Jiang, Shujing Xu, Q. Cui, Ruikun Du, Dongwei Kang, P. Zhan, L. Rong, Xin Liu","doi":"10.16438/J.0513-4870.2020-0131","DOIUrl":"https://doi.org/10.16438/J.0513-4870.2020-0131","url":null,"abstract":"The epidemic caused by coronavirus poses a serious threat to human health, but there is no specific drug or vaccine for the treatment of this kind of virus infection Herein, this article selects typical case studies in recent years and reviews the medicinal chemistry strategies of anti-SARS-CoV, MERS-CoV and other coronavirus drugs from the perspective of medicinal chemistry, and tries to provide some clues to current drug research against-SARS-CoV-2","PeriodicalId":7092,"journal":{"name":"Acta pharmaceutica Sinica","volume":"67 1","pages":"537-553"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84048855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of chemical drugs applied for clinical trial for the treatment of COVID-19 新冠肺炎临床试验化学药物应用分析
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-03-01 DOI: 10.16438/J.0513-4870.2020-0151
Chao Zhang, S. Chen, Jie Zhang, Ying Guo
The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout China and many other countries around the world. The antivirals are important measures to this epidemic; however, there is no drug approved for against coronavirus yet. With the continuously rising number of confirmed/suspected cases of COVID-19, it is urgent to obtain antiviral drugs for the clinical treatment. In response to this situation, drug repurposing strategy becomes one of the best approaches for anti-SARS-CoV-2 drug discovery. By retrieving the clinical trials registered in Chinese Clinical Trial Registry and ClinicalTrials.gov, a total of 14 chemical drugs were registered for COVID-19. In this review, we summarize and analyze the 14 drugs' indications, targets, and research basis related to the activities against viral infections, esp. coronavirus infections. We are making efforts to understand the evidence basis of these drugs for the treatment of SARS-CoV-2 infection applied by various research and clinical institutions in response to this COVID-19 outbreak, and also providing clues for quick response to possible epidemic in future and reasonable expansion of the indications of drugs.
由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)已在中国和世界许多国家蔓延。抗病毒药物是防治这一流行病的重要措施;然而,目前还没有批准用于治疗冠状病毒的药物。随着新冠肺炎确诊/疑似病例不断增加,迫切需要获得抗病毒药物用于临床治疗。针对这种情况,药物再利用策略成为抗sars - cov -2药物发现的最佳途径之一。通过检索在中国临床试验注册中心和ClinicalTrials.gov注册的临床试验,共有14种化学药物注册用于COVID-19。本文就14种药物抗病毒感染特别是冠状病毒感染的适应症、靶点、研究基础等方面进行综述和分析。我们正在努力了解这些治疗SARS-CoV-2感染的药物在各研究和临床机构应对此次COVID-19疫情中应用的证据基础,并为未来可能发生的疫情快速反应和合理扩大药物适应症提供线索。
{"title":"Analysis of chemical drugs applied for clinical trial for the treatment of COVID-19","authors":"Chao Zhang, S. Chen, Jie Zhang, Ying Guo","doi":"10.16438/J.0513-4870.2020-0151","DOIUrl":"https://doi.org/10.16438/J.0513-4870.2020-0151","url":null,"abstract":"The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout China and many other countries around the world. The antivirals are important measures to this epidemic; however, there is no drug approved for against coronavirus yet. With the continuously rising number of confirmed/suspected cases of COVID-19, it is urgent to obtain antiviral drugs for the clinical treatment. In response to this situation, drug repurposing strategy becomes one of the best approaches for anti-SARS-CoV-2 drug discovery. By retrieving the clinical trials registered in Chinese Clinical Trial Registry and ClinicalTrials.gov, a total of 14 chemical drugs were registered for COVID-19. In this review, we summarize and analyze the 14 drugs' indications, targets, and research basis related to the activities against viral infections, esp. coronavirus infections. We are making efforts to understand the evidence basis of these drugs for the treatment of SARS-CoV-2 infection applied by various research and clinical institutions in response to this COVID-19 outbreak, and also providing clues for quick response to possible epidemic in future and reasonable expansion of the indications of drugs.","PeriodicalId":7092,"journal":{"name":"Acta pharmaceutica Sinica","volume":"33 1","pages":"355-365"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90595048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
[Synthesis and biological evaluation of novel pleuromutilin derivatives with nitrogen-containing heterocycles as antibacterial agents]. [含氮杂环的新型胸腺嘧啶衍生物作为抗菌剂的合成和生物学评价]。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2015-10-01
Xin-yang Wang, Min Chen, Duo Wang, Xiang-dong Chen, Yong Ling, Xiao-li Wang, Hui Wang

A series of new pleuromutilins derivatives were designed and synthesized through coupling 2-aminothiazole ring of WL001 with different nitrogen-containing substituted heterocycles in the side chain. Their biological activities were evaluated against both Gram-positive and Gram-negative clinical bacteria in vitro Most new compounds displayed specificity to certain strain of bacteria. Particularly, compounds with saturated nitrogen-containing heterocycles exhibited significant antibacterial activities (0.062 5-8 µg · mL(-1)) superior or similar to those of amoxicillin, tiamulin and levofloxcin. Furthermore, treatment with 15a and 15b having piperidine or morpholine residues also could effectively inhibit Gram-negative bacteria. Therefore, our novel findings may provide a new insight into the design of novel pleuromutilin derivatives and lay the basis for further studies on the treatment of drug-resistance of pathogenic bacteria.

通过将 WL001 的 2- 氨基噻唑环与侧链中不同的含氮取代杂环偶联,设计并合成了一系列新的胸腺嘧啶衍生物。大多数新化合物对某些菌株具有特异性。尤其是含饱和氮杂环的化合物,其抗菌活性(0.062 5-8 µg - mL(-1))明显优于或类似于阿莫西林、替米考林和左氧氟沙星。此外,具有哌啶或吗啉残基的 15a 和 15b 也能有效抑制革兰氏阴性菌。因此,我们的新发现可为新型胸腺嘧啶衍生物的设计提供新的思路,并为进一步研究治疗病原菌耐药性奠定基础。
{"title":"[Synthesis and biological evaluation of novel pleuromutilin derivatives with nitrogen-containing heterocycles as antibacterial agents].","authors":"Xin-yang Wang, Min Chen, Duo Wang, Xiang-dong Chen, Yong Ling, Xiao-li Wang, Hui Wang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A series of new pleuromutilins derivatives were designed and synthesized through coupling 2-aminothiazole ring of WL001 with different nitrogen-containing substituted heterocycles in the side chain. Their biological activities were evaluated against both Gram-positive and Gram-negative clinical bacteria in vitro Most new compounds displayed specificity to certain strain of bacteria. Particularly, compounds with saturated nitrogen-containing heterocycles exhibited significant antibacterial activities (0.062 5-8 µg · mL(-1)) superior or similar to those of amoxicillin, tiamulin and levofloxcin. Furthermore, treatment with 15a and 15b having piperidine or morpholine residues also could effectively inhibit Gram-negative bacteria. Therefore, our novel findings may provide a new insight into the design of novel pleuromutilin derivatives and lay the basis for further studies on the treatment of drug-resistance of pathogenic bacteria.</p>","PeriodicalId":7092,"journal":{"name":"Acta pharmaceutica Sinica","volume":"50 10","pages":"1297-304"},"PeriodicalIF":0.0,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effect of WS070117M1 on chronic obstructive pulmonary disease in mice and the underling mechanisms of anti-inflammation]. [WS070117M1对小鼠慢性阻塞性肺病的影响及抗炎的内在机制]。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2015-08-01
Shu-hua Cao, Ling-ling Xuan, Dong-mei Wang, Jian-lin Xie, Ren-tao Jiang, Jin-ye Bai, Song Wu, Qi Hou

The aim of this study is to investigate the anti-inflammatory effect of the adenosine derivative N6-(3-hydroxylaniline) adenosine (WS070117M1) on cigarette smoke plus LPS (lipopolysaccharide)-induced chronic obstructive pulmonary disease (COPD) in mice and its mechanism. COPD model was established by exposing male BALB/c mice to cigarette smoke and challenged with LPS inhalation. Supernatants of bronchoalveolar lavage fluid (BALF) were harvested and IL-1β, IL-6, IL-8 and TGF-β1 levels were measured by ELISA (enzyme-linked immunesorbent assay). The number of total white blood cells and neutrophils in bronchoalveolar lavage fluid was counted separately. Lung tissue was stained with Mayer 's hematoxylin and eosin for histopathologic examination. pAMPKa protein expression and distribution of lung tissue were analyzed by immunohistochemistry method. In vitro, levels of AMPKα phosphorylation in phorbol-12- myristate-13-acetate (PMA) differentiated THP-1 cells was detected by immunohistochemistry, IL-8 level in supernatants of cigarette smoke condensate stimulating PMA differentiated THP-1 cells was measured by ELISA. The results showed that WS070117M1 treatment significantly activated AMPKa in the lung tissue. It also resulted in down regulation of IL-1β, IL-6, IL-8 and TGF-β1 levels in bronchoalveolar lavage fluid and IL-8 level in cigarette smoke condensate stimulating PMA differentiated THP-1 cells. In addition, WS070117M1 could inhibit the recruitment of total white blood cells and neutrophils. These results suggest that WS070117M1 may alleviate the airway inflammation by activating AMPK in the lung tissue.

本研究旨在探讨腺苷衍生物 N6-(3-羟基苯胺)腺苷(WS070117M1)对香烟烟雾加 LPS(脂多糖)诱导的小鼠慢性阻塞性肺病(COPD)的抗炎作用及其机制。通过让雄性 BALB/c 小鼠接触香烟烟雾并吸入 LPS,建立了慢性阻塞性肺病模型。采集支气管肺泡灌洗液(BALF)的上清液,用酶联免疫吸附试验(ELISA)测定IL-1β、IL-6、IL-8和TGF-β1的水平。分别计算支气管肺泡灌洗液中的白细胞总数和中性粒细胞数。用免疫组化方法分析肺组织中 pAMPKa 蛋白的表达和分布。在体外,用免疫组化法检测磷酸化AMPKα在磷酸-12-肉豆蔻酸-13-醋酸酯(PMA)分化的THP-1细胞中的磷酸化水平,用ELISA法测定香烟烟气冷凝物刺激PMA分化的THP-1细胞上清液中IL-8的水平。结果表明,WS070117M1 能显著激活肺组织中的 AMPKa。WS070117M1还能降低支气管肺泡灌洗液中IL-1β、IL-6、IL-8和TGF-β1的水平,以及烟雾冷凝物刺激PMA分化的THP-1细胞中IL-8的水平。此外,WS070117M1 还能抑制总白细胞和中性粒细胞的募集。这些结果表明,WS070117M1 可通过激活肺组织中的 AMPK 来缓解气道炎症。
{"title":"[Effect of WS070117M1 on chronic obstructive pulmonary disease in mice and the underling mechanisms of anti-inflammation].","authors":"Shu-hua Cao, Ling-ling Xuan, Dong-mei Wang, Jian-lin Xie, Ren-tao Jiang, Jin-ye Bai, Song Wu, Qi Hou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this study is to investigate the anti-inflammatory effect of the adenosine derivative N6-(3-hydroxylaniline) adenosine (WS070117M1) on cigarette smoke plus LPS (lipopolysaccharide)-induced chronic obstructive pulmonary disease (COPD) in mice and its mechanism. COPD model was established by exposing male BALB/c mice to cigarette smoke and challenged with LPS inhalation. Supernatants of bronchoalveolar lavage fluid (BALF) were harvested and IL-1β, IL-6, IL-8 and TGF-β1 levels were measured by ELISA (enzyme-linked immunesorbent assay). The number of total white blood cells and neutrophils in bronchoalveolar lavage fluid was counted separately. Lung tissue was stained with Mayer 's hematoxylin and eosin for histopathologic examination. pAMPKa protein expression and distribution of lung tissue were analyzed by immunohistochemistry method. In vitro, levels of AMPKα phosphorylation in phorbol-12- myristate-13-acetate (PMA) differentiated THP-1 cells was detected by immunohistochemistry, IL-8 level in supernatants of cigarette smoke condensate stimulating PMA differentiated THP-1 cells was measured by ELISA. The results showed that WS070117M1 treatment significantly activated AMPKa in the lung tissue. It also resulted in down regulation of IL-1β, IL-6, IL-8 and TGF-β1 levels in bronchoalveolar lavage fluid and IL-8 level in cigarette smoke condensate stimulating PMA differentiated THP-1 cells. In addition, WS070117M1 could inhibit the recruitment of total white blood cells and neutrophils. These results suggest that WS070117M1 may alleviate the airway inflammation by activating AMPK in the lung tissue.</p>","PeriodicalId":7092,"journal":{"name":"Acta pharmaceutica Sinica","volume":"50 8","pages":"986-92"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A new flavonol glycoside from Baeckea Frutescens L]. [一种新的黄酮醇苷,来自白花蛇舌草)。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2008-10-01
Wen-jie Lu, Qi-kang Ya, Jia-yuan Chen, Bu-ming Liu

To study the chemical constituents of the traditional Chinese herb Baeckea Frutescens L., a new flavonol glycoside, named 6, 8-dimethylkaempferol-3-O-alpha-L-rhamnoside (1), together with seven known compounds: quercetin (2), quercetin-3-O-alpha-L-rhamnoside (3), myricetin (4), myricetin-3-O-alpha-L-rhamnoside (5), gallic acid (6), ursolic acid (7) and 1,3-dihydroxy-2-(2'-methoxylpropionyl)-5-methoxy-6-methylbenzene (8) were isolated by using silica gel column chromatography, polyamide column chromatography and recrytallization. Their structures were identified on the basis of physicochemical properties and spectroscopic analysis. Among them, compounds 2-7 were isolated from this plant for the first time and compound 8 was first isolated from plant.

为了研究传统中草药白花蛇舌草(Baeckea Frutescens L.)的化学成分、一种名为 6,8-二甲基堪非醇-3-O-alpha-L-鼠李糖苷(1)的新黄酮醇苷,以及七种已知化合物:通过硅胶柱色谱法、聚酰胺柱色谱法和重结晶法,分离出了名为 6,8-二甲基堪非醇-3-O-alpha-L-鼠李糖苷(1)的新黄酮醇苷,以及七种已知化合物:槲皮素(2)、槲皮素-3-O-alpha-L-鼠李糖苷(3)、杨梅素(4)、杨梅素-3-O-alpha-L-鼠李糖苷(5)、没食子酸(6)、熊果酸(7)和 1,3-二羟基-2-(2'-甲氧基丙酰基)-5-甲氧基-6-甲基苯(8)。根据理化性质和光谱分析确定了它们的结构。其中,化合物 2-7 是首次从该植物中分离出来,化合物 8 是首次从该植物中分离出来。
{"title":"[A new flavonol glycoside from Baeckea Frutescens L].","authors":"Wen-jie Lu, Qi-kang Ya, Jia-yuan Chen, Bu-ming Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To study the chemical constituents of the traditional Chinese herb Baeckea Frutescens L., a new flavonol glycoside, named 6, 8-dimethylkaempferol-3-O-alpha-L-rhamnoside (1), together with seven known compounds: quercetin (2), quercetin-3-O-alpha-L-rhamnoside (3), myricetin (4), myricetin-3-O-alpha-L-rhamnoside (5), gallic acid (6), ursolic acid (7) and 1,3-dihydroxy-2-(2'-methoxylpropionyl)-5-methoxy-6-methylbenzene (8) were isolated by using silica gel column chromatography, polyamide column chromatography and recrytallization. Their structures were identified on the basis of physicochemical properties and spectroscopic analysis. Among them, compounds 2-7 were isolated from this plant for the first time and compound 8 was first isolated from plant.</p>","PeriodicalId":7092,"journal":{"name":"Acta pharmaceutica Sinica","volume":"43 10","pages":"1032-5"},"PeriodicalIF":0.0,"publicationDate":"2008-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in chromatography 色谱法研究进展
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 1983-12-01 DOI: 10.1201/crcadvchroma
Zhou Th
329 The volume of M.S. Tswett’s selected works pre pared by the Russian Academy of Sciences includes the major part of the body of the doctoral dissertation by the inventor of chromatography, defended in 1911. This voluminous dissertation was published as a sepa rate monograph (Khromofilly v Rastitel’nom i Zhivot nom Mire (Chromophylls in the Plant and Animal Kingdom), Warsaw, 1910)). Though the title of the book was not “chromatographic,” it described the results of the author’s work on the technique of chro matography. However, the first book devoted to this method is usually considered Zechmeister and Chol noky’s monograph published in German in 1937 [1]; it played a significant role in the development of chro matography, in the approval of its name, and the rec ognition of Tswett’s priority.
329 .俄罗斯科学院准备的ms . Tswett选集包括色谱法发明者1911年答辩的博士论文主体的主要部分。这篇长篇论文以sepa rate专著的形式出版(Khromofilly v Rastitel 'nom i Zhivot nom Mire(植物和动物王国的色素),华沙,1910))。虽然这本书的标题不是“色谱”,但它描述了作者在色谱技术方面的工作成果。然而,致力于这种方法的第一本书通常被认为是1937年在德国出版的泽克迈斯特和乔尔诺基的专著[1];它在色谱法的发展中发挥了重要作用,在其名称的批准,并承认特威特的优先权。
{"title":"Advances in chromatography","authors":"Zhou Th","doi":"10.1201/crcadvchroma","DOIUrl":"https://doi.org/10.1201/crcadvchroma","url":null,"abstract":"329 The volume of M.S. Tswett’s selected works pre pared by the Russian Academy of Sciences includes the major part of the body of the doctoral dissertation by the inventor of chromatography, defended in 1911. This voluminous dissertation was published as a sepa rate monograph (Khromofilly v Rastitel’nom i Zhivot nom Mire (Chromophylls in the Plant and Animal Kingdom), Warsaw, 1910)). Though the title of the book was not “chromatographic,” it described the results of the author’s work on the technique of chro matography. However, the first book devoted to this method is usually considered Zechmeister and Chol noky’s monograph published in German in 1937 [1]; it played a significant role in the development of chro matography, in the approval of its name, and the rec ognition of Tswett’s priority.","PeriodicalId":7092,"journal":{"name":"Acta pharmaceutica Sinica","volume":"6 1","pages":"976"},"PeriodicalIF":0.0,"publicationDate":"1983-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88167168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta pharmaceutica Sinica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1